Eli Lilly has added another candidate to a growing pipeline of therapies for amyotrophic lateral sclerosis (ALS), tapping UK ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.